Strong execution raises FY27 guidance; capex and peptides emerging risks
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Q2 beat initial 15% FY27 revenue growth guidance and delivered 21.4% EBITDA margin (vs 20% FY26 target). Raising guidance credible given H1 momentum.
Optimistic
next 1–2 quarters
Optimistic
multi-year
SMS delivered strong Q2 with 30% revenue and 57% PAT growth, backed by ibuprofen volumes and backward integration margin gains. Management raised FY27 guidance credibly on H1 momentum; EBITDA margin pathway to 22-24% next year is achievable. Peptide entry and new molecule pipeline offer multi-year optionality, though early-stage execution risk remains. Key risk: raw material price volatility (acknowledged for 1-2 quarters) and high capex deployment (₹120Cr pending) into constrained balance sheet.
₹316.1 Cr
Revenue · +30.4% YoY₹39.9 Cr
Reported PAT · +57.4% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 30% YoY to ₹316Cr
METDelivered ₹316.1Cr, 30.4% YoY growth — exact match
EBITDA grew 40% to ₹68Cr with 21% margin
METImplies ₹48.6Cr prior Q2; 21.4% OPM delivered, consistent with EBITDA claim
PAT grew 57% to ₹39.6Cr, 13% margin
METDelivered ₹39.9Cr PAT, 12.6% NPM, 57.4% YoY growth — supported, margin slightly lower
Ibuprofen capacity at 90-95% utilization, volumes ramping 450-500 T/month
MET10-15% volume growth cited YoY; implies ~50-80 T/month incremental — plausible with stated utilization
HVA contribution ₹49% of H1 revenue from 47% FY26
METImplies HVA revenue ~₹256Cr H1, ~₹107Cr H1 commodity — reasonable for portfolio mix
Earnings quality
What changed since the last call
FY27 revenue guidance raised
UpgradePrior: 15% growth guidance. Now: expect to exceed both revenue and 20% EBITDA margin (H1 at 19% revenue growth, implying 17-20% full-year). Upgrade driven by ibuprofen pricing realization and backward integration.
Ibuprofen margin expansion accelerated
UpgradeBackward integration <10% margin → teens now, driving 145 bps EBITDA margin expansion Q1 to Q2 FY27 (20% to 21.4%), path to 22-24% FY28.
Capex spending profile clarified
Neutral₹280Cr total; ₹160Cr deployed H1, ₹120Cr remaining before end FY27. Peak debt ₹400Cr by FY27-end (both short/long-term).
Peptide R&D timeline extended
NeutralStarted a few months back; samples Q4 FY27 (not Q2/Q3). Meaningful revenue 2-3 years out, not next year. CDMO facility coming online for peptides; CRO path TBD.
The Q&A
Analysts pressed hard on ibuprofen margin sustainability, capex funding, and peptide credibility. Management acknowledged commodity price cyclicality but stood firm on backward integration advantage and cost control. Deflected on exact ibuprofen margin (called teens EBITDA) and avoided peer cost comparisons. Overall held tone; no major concessions.
Peptides market entry — Nirali Shah, Ashika Investment Managers
PartialEvaluating 2 opportunities, 2 leads. Generic peptides and cosmetic peptides. Targeting Tier B/C customers first, then Tier A CDMO. Expecting meaningful revenue 2-3 years out. Samples by Q4 FY27.
Ibuprofen capacity utilization — Nirali Shah, Ashika Investment Managers
AnsweredCurrently 90-95% utilized, 450-500 T/month. Capex ongoing to reach 9,600 MT. Completed in next few quarters. 90% occupancy expected in 6-9 month span post-completion.
Ibuprofen pricing power — Raj Agrawal, Niveshaay Asset Management
AnsweredYes, definitely possible. Cyclical commodity. Up phases and down phases with shortages and overcapacity. Equipped to handle all phases. Derivatives also in production.
Ibuprofen cost structure vs peers — Raj Agrawal, Niveshaay Asset Management
PartialHonest answer: don't know peers' processes. SMS has best manufacturing processes for ibuprofen. Backward integration already done below 10% margin. Big advantage now.
Ibuprofen margin beneficiary timing — Bhavika, Niveshaay Asset Management
PartialBefore backward integration, margin <10%. EBITDA margins in teens now. Stability on product more important than margin expansion right now. Cannot disclose exact profit margin on ibuprofen.
Capex deployment and debt — Vignesh Iyer, Sequent Investments
AnsweredTotal ₹280Cr capex. ₹160Cr deployed to date. ₹120Cr remaining to be deployed by end FY27. Peak debt ₹400Cr (both short and long-term).
Partnership with Chemo — Nirali Shah, Ashika Investment Managers
Answered10-year partnership ongoing. JV model: joint development, joint marketing, profit share. Products: sitagliptins, flozins, and few others.
Long-term growth drivers beyond ibuprofen — Nirali Shah, Ashika Investment Managers
AnsweredConsolidating existing business. Peptides is one big area of focus. Strong team on peptides; good advantage there. Fairly early into peptide market. Patent cliff in FY29 also an opportunity.
Q2 revenue growth breakdown — Maitri Shah, Sapphire Capital
AnsweredVolume growth 10-15%. Price realization hikes taken and completed.
Raw material cost headwinds — Maitri Shah, Sapphire Capital
AnsweredPressure ongoing, expected to continue 1-2 quarters. Global scenario. Increased raw material prices likely to persist.
High-value API revenue contribution — Maitri Shah, Sapphire Capital
AnsweredHVA ~49% of H1 revenue (from 47% FY26). 6-8 new molecules/launches in FY28. EBITDA margins to improve once launched and commercial. Non-commodity ibuprofen driving growth.
FY28 EBITDA margin target — Maitri Shah, Sapphire Capital
Answered22-24% range. Assumes raw material easing by then and high-value product share increase.
Ibuprofen future revenue share — Maitri Shah, Sapphire Capital
AnsweredBelow 30% or around 30-35% with increased capacity. Not a single product company. Non-dependency target <35% on any single product.
Peptide CRO/CDMO path — Maitri Shah, Sapphire Capital
AnsweredOwn generic peptide development. CRO pilot to Q2 FY28. Own APIs, not outsourced CRO. Pilot scale by Q4 FY27.
Asset turnover trajectory — Mudit Daga, Merlin Holdings
AnsweredCurrent 1.46x (with capex WIP), 1.72x (excluding capex WIP). 2-3 year target: 1.75x. Asset utilization improving post-capex completion.
Working capital cycle and cash conversion — Vandit Dharamshi, Anantra Growth Capital
AnsweredWC improved significantly. WC cycle 120-150 days reasonable for next 3-4 years (commodity ibuprofen domestic sales have higher credit terms). Cash conversion: 93% H1, expect 95% going forward. Long-term target 72% improvement over 5-7 years.
Guidance
FY27 revenue growth now expected to exceed initial 15% guidance
HighH1 at 19% growth to ₹523Cr. Strong ibuprofen volumes + price hikes + HVA growth. Implying 13% H2 growth to beat 15% FY27 target.
EBITDA margin targeting 22-24% in FY28
MediumFrom 21% Q2 FY27. Assumes raw material easing in 1-2 quarters, HVA share increase to 50%+, new molecule launches contributing. Backward integration benefit ongoing.
₹280Cr total capex; ₹120Cr remaining deployment by end FY27
HighIbuprofen capacity addition to 9,600 MT/year (from ~7,500 MT now). Peptide facility buildout. Completion Q1-Q3 FY27 expected.
Risks the call surfaced
Commodity price cyclicality
High50% of H1 revenue from ibuprofen. Management expects 1-2 quarters of raw material price pressure. Ibuprofen is a cyclical commodity with up/down phases. Margin upside dependent on pricing power, not fundamental cost structure.
Capex execution
High₹280Cr total capex program to expand ibuprofen capacity to 9,600 MT. ₹120Cr remaining deployment before end FY27 (4-6 month window). Peak debt ₹400Cr expected. Execution delays could impact revenue growth and margin improvement assumptions.
Peptide commercialization risk
MediumPeptides R&D started a few months ago. Pilot samples Q4 FY27 target. Meaningful revenue 2-3 years out. Management lacks concrete customer commitments; CRO/CDMO path still being evaluated. Key growth driver but highly uncertain.
Ibuprofen margin compression
MediumPrior ibuprofen margin <10%; now teens EBITDA but management cautious on quantification. Derivatives (non-regular ibuprofen) being developed; profitability TBD. Raw material price pressure expected 1-2 more quarters. If commodity prices spike, margin upside could reverse.
High-value API concentration
MediumHVA 49% of H1 revenue, up from 47% FY26. Portfolio includes ARV, anti-migraine, anti-epileptic, anti-ED, antibiotic. No customer concentration details disclosed. Regulatory/pricing pressure on any large HVA customer could impact earnings.
Debt leverage & interest burden
LowPeak debt ₹400Cr by FY27-end (both short and long-term). Interest expense already impacting H1 PAT margin (₹15+Cr incremental interest cited). Debt serviceability dependent on sustained EBITDA growth and capex completion on schedule.
Management
Score 7/10. Clear on capex deployment, revenue growth drivers, and margin trajectory. Candid on raw material headwinds and ibuprofen cyclicality. Deflected on exact ibuprofen profit margin and avoided peer cost comparisons (citing lack of knowledge of competitors' processes). Delivered 30% revenue growth and 57% PAT growth in Q2 FY27, meeting/beating prior guidance. Capex 50% deployed on schedule. 6 DMF/CEP filings completed H1 (on track for 10 FY27). Backward integration margin improvement visible.
1 · Q3-Q4 FY27
Complete ibuprofen capacity expansion to 9,600 MT; ramp utilization from 90-95% to ±90% of full 9,600 MT by mid-FY28
2 · Q4 FY27
Pilot-level peptide samples ready for customer evaluation; CRO scaling path visible by Q2 FY28
3 · FY28
6-8 new high-value API launches; non-commodity ibuprofen derivatives; EBITDA margin target 22-24% realized
Key risk: raw material price volatility (acknowledged for 1-2 quarters) and high capex deployment (₹120Cr pending) into constrained balance sheet.
Strong Execution on Backward Integration — But Can It Hold Through the Commodity Cycle?
SMS delivered a 30% revenue beat and raised FY27 guidance, backed by ibuprofen pricing and margin gains from backward integration. The risk: half the growth is driven by commodity cyclicality management expects to soften within 1–2 quarters, and a heavy capex program looms ahead.
₹316.1 Cr
+30.4% YoY, +52.7% QoQ
₹39.9 Cr
+57.4% YoY, +90.6% QoQ
21.4%
expanded 145 bps QoQ from Q1
Raised
now expect to exceed 15% target
The headline numbers are strong: Q2 revenue surged 30% YoY and PAT nearly doubled. Management backed this up by raising FY27 guidance, signalling confidence in the momentum. But the composition of that growth tells a different story. Half of the first-half revenue comes from ibuprofen—a cyclical commodity where prices are driving the majority of the gain. Management itself expects raw material cost pressure to continue for 1–2 quarters, which suggests the margin tailwind will soon face headwinds.
The ibuprofen story: pricing power, not volumes
H1 FY27 revenue landed at ₹523 Cr, up 19% YoY. Of that, roughly ₹150–160 Cr (50%) came from ibuprofen, a commodity API where SMS is ramping capacity from 90–95% utilization at 450–500 tonnes per month. Volume growth is strong but modest in absolute terms: management cited 10–15% YoY volume increase. The real story is pricing. Q2's 30% revenue jump was 30% price-driven, 10–15% volume-driven. That ratio is the risk. Commodities are cyclical; when capacity balances across the industry and global supply normalizes, pricing power evaporates.
It's a cyclical product, and it goes through many phases. There will be up phases, there will be down phases, there will be shortages, there'll be overcapacity.
Backward integration: real, but hedged
The margin expansion—145 bps QoQ, EBITDA margin to 21.4%—is driven by backward integration of ibuprofen raw materials. Prior to in-house production, ibuprofen EBITDA margin was below 10%; now it sits in the 'teens' (management declined to disclose exact %). This is structural and real. But management also signalled caution: they emphasised product stability and cost control as priorities, not margin expansion. And they expect raw material inflation to persist for 1–2 more quarters. In other words, the 145 bps gain is partly a catch-up from commodity deflation, not entirely a structural moat.
Revenue grew 30% YoY to ₹316 Cr
Exact matchDelivered ₹316.1 Cr, 30.4% YoY growth
PAT grew 57% to ₹39.6 Cr
Exact matchDelivered ₹39.9 Cr, 57.4% YoY growth
EBITDA grew 40% with 21% margin
SupportedImplies ₹48.6 Cr prior Q2; OPM 21.4% delivered
Ibuprofen utilization 90–95%, volumes ramping 450–500 T/month
Supported10–15% volume growth YoY consistent with stated utilization
HVA now 49% of H1 revenue, up from 47% FY26
SupportedImplies ~₹256 Cr HVA in H1; portfolio mix improving
What changed on this call
FY27 revenue guidance raised: from 15% target to now expecting to exceed, backed by H1 19% growth
EBITDA margin target clarified: 22–24% for FY28 (vs. prior 20% FY26 aspiration), assumes raw material easing
Capex timeline and debt quantified: ₹280 Cr total, ₹160 Cr deployed H1, ₹120 Cr remaining before FY27-end. Peak debt ₹400 Cr.
Peptide R&D timeline extended: samples Q4 FY27 target, meaningful revenue 2–3 years out (not next year)
HVA revenue share grew from 47% FY26 to 49% H1; targeting <35% dependency on any single product
Backward integration margin gain: <10% → teens EBITDA on ibuprofen. Real and structural.
H1 growth momentum (19% YoY) and EBITDA margin (21%) support FY27 guidance raise.
HVA diversification: 49% of H1 revenue, growing, higher-margin than ibuprofen.
Ibuprofen 50% of H1 revenue; 30% of Q2 growth is pricing, not volume.
Raw material inflation expected 1–2 more quarters; margin tailwind will face headwinds.
Capex execution risk: ₹120 Cr remaining; peak debt ₹400 Cr creates leverage constraint.
Peptides early-stage; no customer wins yet; 2–3 year revenue timeline remains speculative.
Management guidance credible on execution and ibuprofen demand; held line on cyclicality risk.
Ibuprofen commodity cyclicality
High50% of H1 revenue is ibuprofen. Pricing drives 30% of Q2 growth; management expects commodity pressure 1–2 quarters. When supply normalizes, pricing power evaporates and margins compress. No structural growth story without volume ramp.
Capex execution and debt leverage
High₹120 Cr capex remaining in 4–6 month window before FY27-end. Peak debt ₹400 Cr by FY27-end constrains balance sheet flexibility. Delays could impact revenue ramp and margin trajectory. Interest burden already material (₹15+ Cr incremental cited).
Peptide commercialization timeline
MediumR&D started a few months ago. Pilot samples Q4 FY27 target; meaningful revenue 2–3 years out. No customer LOIs or pilot contracts signed as of call. Key long-term growth driver but highly uncertain execution.
Raw material price inflation
MediumOngoing pressure expected 1–2 more quarters. Gross margin headwind even with backward integration; cost control ongoing (batch sizes ~10 tons now). If inflation persists longer, margin expansion stalls.
High-value API concentration
MediumHVA 49% of H1, up from 47% FY26. No customer concentration details disclosed. Regulatory or pricing pressure on any large HVA customer (ARV, anti-ED, antibiotic) could impact earnings. Diversification ongoing (6–8 new launches FY28) but still speculative.
How the street is positioned
The stock is priced at ₹513.2 as of this report, near its all-time high of ₹535 (only 4% below ATH). It has rallied 90% from its 52-week low of ₹270. The trend is BULLISH, but RSI at 63 (NEUTRAL) suggests limited near-term upside without a fresh catalyst. The market has repriced the stock for the guidance raise and backward integration margin improvement. Foreign institutional inflows are picking up: FII stake rose to 0.65% in Q1 FY27 from 0.31% in Q4 FY26 (+34 bps inflow). Domestic institutions trimmed slightly (DII 2.83% from 3.02%); promoters unchanged at 68.07%. Block deal activity shows routine trading with no insider selling near highs. The tape confirms the bulls are in control, but valuation and positioning leave little room for surprise. The next move likely hinges on whether raw material costs stabilize faster than expected or capex execution hiccups.
1 · Raw material price trend (next 1–2 quarters)
Management's 1–2 quarter guidance is the key risk. If global prices normalize sooner, margin upside to FY28 target (22–24%) is intact. If inflation persists, the 145 bps Q1–Q2 gain will reverse.
2 · Capex completion and debt servicing (Q1–Q3 FY27)
₹120 Cr remaining to deploy by FY27-end. Completion of 9,600 MT ibuprofen capacity would unlock incremental ~₹100 Cr+ revenue at scale. Debt peak ₹400 Cr is manageable if EBITDA grows 20%+ but becomes a constraint if growth stalls.
3 · Peptide samples and customer engagement (Q4 FY27)
Q4 FY27 target for pilot samples. Any CRO/CDMO customer LOI or pilot contract would materially de-risk the 2–3 year revenue pathway and justify the long-term growth thesis.
4 · HVA new molecule launches (FY28)
6–8 launches on track. These are critical to reduce ibuprofen dependency to <35%. Evidence of regulatory approval or customer acceptance would validate the portfolio diversification thesis.
SMS delivered solid execution on backward integration and raised FY27 guidance credibly on H1 momentum. But the growth is driven by ibuprofen commodity pricing and margin expansion that management itself expects to soften in 1–2 quarters. The capex program (₹120 Cr remaining, ₹400 Cr peak debt) and peptide timeline (2–3 years to revenue) add execution risk. The stock is already near all-time highs with FII buying in. The number to track from here is organic volume growth and raw material cost stabilization, not headline profit. Execution on capex and capex-driven capacity ramp is the near-term catalyst; peptides and new molecules are the long-term optionality. Until raw material pressure eases and organic growth becomes the driver, the upside is hedged.
SMS Pharma Q2 FY27: PAT +57% YoY to ₹39.9 Cr on consolidated basis, margins expand
PAT +57.44% YoY · revenue +30.39% · margins expanding
₹316.09 Cr
+30.39% YoY
₹39.85 Cr
+57.44% YoY
12.55%
+2.2pp YoY
₹4.26
SMS Pharmaceuticals' consolidated PAT (net profit after tax plus share of associate profit) rose 57.4% YoY to ₹39.85 Cr from ₹25.31 Cr in Q2 FY26, on revenue from operations of ₹316.09 Cr, up 30.4% YoY from ₹242.43 Cr. Standalone PAT was ₹39.13 Cr (EPS ₹4.18) against consolidated EPS of ₹4.26. Sequentially, both revenue (+52.7% QoQ) and PAT (+90.6% QoQ) jumped sharply off a comparatively soft Q1 FY27 base (₹206.96 Cr revenue, ₹20.91 Cr PAT) — a volume-driven swing typical of API/bulk-drug order execution rather than a seasonal effect, so the YoY read is the one that should anchor the verdict.
Q2 FY-2027 vs prior quarters
Margins expanded on both counts: OPM (EBITDA on revenue from operations, excluding other income) rose to 21.40% from 19.95% a year ago and 19.79% last quarter; NPM (PAT/total income) rose to 12.56% from 10.38% YoY. The main driver was operating leverage — manufacturing expenses eased to 7.85% of revenue from 10.61% a year ago — even as employee costs ticked up modestly (8.62% vs 7.94% of revenue) ahead of the company's capacity and peptides/CDMO build-out. Finance cost was flat YoY in absolute terms (₹573.57 Cr vs ₹573.62 Cr) despite the much higher revenue base, further aiding the margin print.
The stock went into the print at ₹508.35, up 6.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records.
For FY27, SMS Pharmaceuticals is guiding for 15% revenue growth with an aim to further improve upon the FY26 EBITDA margin of 20%. Management believes there is potential to exceed this guidance if external factors like geopolitical uncertainties and logistics stabilize. The company sees long-term growth potential with
— This quarter: beat
No street estimates for this quarter were found in a web search, so vsStreet is unknown — SMS Pharma does not appear to carry formal sell-side coverage with published quarterly previews. Against management's own FY27 guidance (15% revenue growth, improving on FY26's ~20% OPM, from the prior concall), the company is tracking ahead: H1 FY27 consolidated revenue is up 19.3% YoY to ₹523.05 Cr against the 15% full-year target, and Q2 OPM of 21.40% is already above the FY26 benchmark the company said it wanted to improve on. No management press release accompanied this filing, so there is no fresh quarter-specific commentary to cross-check against the print.
W1
Whether the ₹50 Cr loan to currently loss-making SMS Peptides (₹0.91 Cr Q2 loss) converts into visible peptides/CDMO revenue per management's guided growth platform.
W2
Whether the 21.40% OPM holds or reverts toward the ~20% FY26 base once the unusually sharp +52.7% QoQ volume jump normalizes.
W3
Resolution and P&L impact of the conflicting Oct 31, 2026 tax appellate outcomes (dismissal vs ₹45.63 Cr demand vacated) in Q3 FY27.
Source in Rs. Lakhs, converted to Cr (÷100). Consolidated PAT ₹39.85 Cr = net profit after tax ₹39.57 Cr (PBT 52.82 − tax 13.25) plus ₹0.28 Cr share of associate (VKT Pharma) profit, matching reported EPS ₹4.26. No exceptional/extraordinary items in current or year-ago quarter, so no adjusted-growth figure is needed. Standalone vs consolidated PAT diverge ~1.8%, immaterial.